v" Although gemistocytic astrocytomas are considered slow-growing astrocytomas, they often behave aggressively. To clarify the biological and clinical behavior of these rare tumors, the authors retrospectively identified 59 patients with gemistocytic astrocytoma whose tumors were diagnosed and treated between June, 1976, and July, 1989. Three patients who were lost to follow-up review were excluded, as were two whose original slides could not be obtained and three whose tumors were diagnosed at recurrence or at autopsy. The pathological material of the remaining 51 patients was reviewed using two sets of histological criteria.
G EM|STOCYTIC astrocytomas are rare tumors, accounting for 21.4% ~E and 24% 2s of all astrocytomas in the earliest studies and 9% to 19% in more recent surveys, j6'2z'25"48 The wide variation in incidence seems to reflect differences in the histological definition. The most specific definition of gemistocytic astrocytoma is given in the classification published by the World Health Organization (WHO): 56 "a tumour composed predominantly of large, plump astrocytes with abundant eosinophilic cytoplasm and one or more, usually eccentric, nuclei." Although gemistocytic astrocytomas are considered Grade 2 astrocytomas in the Kernohan-Sayre system, 23 they show a propensity for anaplastic transformation. 38 Data on their biological and clinical behavior are scarce but generally seem to support this observation. 1~
In an autoradiographic study of gliomas exposed to tritiated thymidine, however, Hoshino, et al., 2~ showed that gemistocytic astrocytes themselves have very little, if any, proliferative potential.
These conflicting data led us to review all patients diagnosed with gemistocytic astrocytoma between June, 1976, and July, 1989. The purpose of this retrospective study was to reconsider the definition of these tumors 
Clinical Material and Methods
A review of the data base of the Neuro-Oncology Service, University of California at San Francisco (UCSF), identified 59 patients with an initial diagnosis of gemistocytic astrocytoma made between June, 1976, and July, 1989. Eight patients were excluded: three who were lost to follow-up review, two whose tumors were diagnosed at recurrence, one whose tumor was found at autopsy, and two whose original slides could not be obtained. The slides of tumor specimens from the initial operation of the remaining 51 patients were reviewed by two of us (H.G.J.K. and R.LD.) using strictly applied criteria.
"Pure" gemistocytic astrocytoma was defined as a glial neoplasm with mere than 60% gemistocytes in all high-power fields and a background of fibrillary astrocytes (Fig. 1) . "Mixed" gemistocytic astrocytoma was defined as a glial neoplasm with 20% to 60% gemistocytes and a background of anaplastic astrocytes (moderately increased cellularity, at least focally; a high nuclear/cytoplasmic ratio; coarse nuclear chromatin; increased mitotic activity; and nuclear or cytoplasmic pleomorphism) (Fig. 2) . Patients whose tumors did not meet these criteria were excluded from the analysis.
The pathological material was also reviewed to identify perivascular lymphocytic infiltration. Lymphocytes were defined as small cells with round, dark-staining nuclei and little or no visible cytoplasm. No attempt was made to classify the degree of perivascular lymphocytic infiltration, and infiltrates near areas of necrosis were not taken into account. In addition, all slides of material obtained during subsequent operations for recurrent tumor were reviewed with special attention to features indicating malignant transformation.
The patients were further analyzed regarding age, Karnofsky Performance Scale score, duration and type of preoperative signs and symptoms, extent of surgery, adjuvant therapy, treatment at recurrence, and duration of survival after the initial operation. If available, the bromodeoxyuridine labeling index was considered an indicator of proliferative potential) 7-~9 Tumor recurrence was assessed by neurological examination and contrast-enhanced computerized tomography? 6 Survival curves were calculated using the method of Kaplan and Meier. 2~ Statistical comparison between groups was performed using the WilcoxonGehan test) 4
Summary of Cases Histopathology
During the 13 years encompassed by this study, several pathologists made the diagnosis of gemistocytic astrocytoma in the total series of 59 patients, almost certainly using various definitions. Therefore, the diagnosis of gemistocytic astrocytoma was confirmed in only 28 patients: 13 with "pure" gemistocytic astrocytoma (Group A) and 15 with "mixed" gemistocytic astrocytoma (Group B). These 28 patients represent approximately 1.3% of all patients seen at the NeuroOncology Service since 1976. According to histological criteria currently used to classify malignant gliomas at UCSF (Table 1 ), 14 of the remaining 23 tumors were glioblastomas multiforme and seven were highly anaplastic astrocytomas. One tumor was reclassified as a subependymal giant-cell astrocytoma and one as a mixed protoplasmic/fibrillary astrocytoma. These 23 tumors were excluded from further analysis.
Perivascular lymphocytic infiltration was identified in 15 (54%) of 28 tumors. The bromodeoxyuridine labeling index was available for one patient in Group A (< 1%) and three patients in Group B (1.1%, 6.5%, Only one tumor showed malignant transformation to glioblastoma multiforme at reoperation (Fig. 2  lower) . In this tumor, originally a "mixed" gemistocytic astrocytoma, all of the histological features we consider essential for the diagnosis of glioblastoma multiforme (Table l) were unequivocally present, and necrosis was seen as well. The other recurrent tumors showed the glioblastoma multiforme a glial neoplasm that is at least focally highly cellular nuclear pleomorphism cytoplasmic pleomorphism vascular endothelial proliferation highly anaplastic astrocytoma not a glioblastoma multiforme at least focally moderately to highly cellular presence of at least two of the following characteristics: high nucLear/cytoplasmic ratio coarse nuclear chromatin much mitotic activity nuclear pleomorphism cytoplasmic pleomorphism typical histological features of astrocytomas after radiation therapy or chemotherapy: focal necrosis, astrocytes with bizarre nuclei, and mural vascular hyalinization. At least focally, some malignant features were also retained (increased cellularity, a high nuclear/cytoplasmic ratio, coarse nuclear chromatin, and mitoses). In six patients, focally prominent gemistocytes were still present.
Clinical Characteristics
The clinical characteristics are summarized in Table  2 . The male:female ratio was 3:1. The median age was significantly higher in Group A than in Group B (48.5 vs. 38.3 years; p < 0.05), The median score on the Karnofsky Performance Scale at presentation was 95% (range 70% to 100%). All tumors were supratentorial and evenly distributed between the left and right hemispheres; 50% of the tumors were frontal and 32% were parietal. The median duration of preoperative symptoms was 21.9 weeks.
The initial signs and symptoms are summarized in Table 3 . The majority of the patients in both groups presented with seizures. Headache, personality changes, and disturbances of speech, reading, or writing were also observed.
Initial Treatment
The initial treatment is summarized in Tables 4 and  5 . All 28 patients underwent surgery followed by radiation therapy. Four patients underwent gross total resection of their tumors as determined from the operative report; 19 had subtotal resection, and five had biopsy only. Ten patients received whole-brain radia- tion therapy (four also received a tumor radiation boost) and 18 received focal irradiation to the tumor plus a 2-to 3-cm margin. High-activity 125I seeds were implanted in the tumor in five patients after external irradiation. The median dose of whole-brain radiation therapy was 50.4 Gy (range 44 to 60 Gy) and that of focal irradiation was 60.6 Gy (range 50.8 to 61.2 Gy). The dose of interstitial brachytherapy ranged from 49 to 60 Gy.
Nineteen patients were diagnosed and treated at UCSF according to protocols used at the time of presentation (Tables 4 and 5 ). The remaining nine patients were initially treated elsewhere and were managed at UCSF for tumor recurrence. All nine patients underwent radiation therapy, and two subsequently received adjuvant chemotherapy (lomustine (CCNU) in one and carmustine (BCNU) in the other). * GA = gemistocytic astrocytoma; subtotal = subtotal resection; gross total = gross total resection; RT = radiation therapy; BCNU = carmustine; BUdR-PCV = bromodeoxyuridine as a parenterally administered radiosensitizer, followed by lomustine (CCNU), procarbazine, and vincristine; 1251-PCV = interstitial brachytherapy with ~2~I, followed by CCNU, procarbazine, and vincristine; HU = hydroxyurea; NU = nitrosourea-based chemotherapy; Proc = procarbazine; AZQ = aziridinylbenzoquinone; IFNB = interferon B; PCV = procarbazine, CCNU, and vincfistine.
t Died of pulmonary embolism.
Alive at time of analysis.
Treatment at Recurrence
Eighteen patients had recurrent tumors. Nine had one recurrence, seven had two recurrences, and two had three recurrences. All 29 recurrences were local; in three patients, a new adjacent lesion developed. Ten patients had one reoperation for tumor recurrence and one had two reoperations; this was followed by J2sI interstitial brachytherapy in one patient and chemotherapy in four others. Chemotherapy alone was given in 13 instances of recurrence, and external reirradiation was administered in two patients (concurrently with BCNU in one). Two patients refused therapy for their second recurrence.
Survival Time
The median survival duration was 136.5 weeks in Group A, 135.6 weeks in Group B, and 140.7 weeks overall. (The slightly higher overall median survival is a mathematical artifact resulting from the linear extrapolation used to calculate median survival.) KaplanMeier 2t survival curves for all 28 patients and for Groups A and B separately are shown in Fig. 3 . Patients who received multimodality therapy postoperatively survived longer than those who received radiation therapy only (144 vs. 124 weeks), but the difference was not statistically significant. Fifteen of the 18 patients with recurrent tumors have died. The 41 , F subtotal RT, ~251-PCV AZQ 106 * GA = gemistocytic astrocytoma; subtotal = subtotal resection; RT = radiation therapy; VCR = vincristine; BCNU = carmustine; CCNU = Iomustine; BUdR-PCV = bromodeoxyuridine as a parenterally administered radiosensitizer, followed by CCNU, procarbazine, and VCR: t251-PCV = interstitial brachytherapy with t25I, followed by CCNU, procarbazine, and VCR: HU = hydroxyurea; Miso = misonidazole; 5-FU = 5-fluorouracil; Proc = procarbazine; IFNB = interferon B; NU = nitrosourea-based chemotherapy; ~251 = interstitial brachytherapy; AZQ = aziridinylbenzoquinone; 6-TG = 6-thioguanine.
§ Alive at time of analysis.
of survival after the first recurrence was 26 weeks. Excluding six patients with insufficient follow-up time and one patient who died of pulmonary embolism, the 5-year survival rate was 23.8% overall (five of 21), 18.2% in Group A (two of 11, with one patient still alive at 310+ weeks), and 30% in Group B (three of 10, with one patient still alive at 460+ weeks). Age correlated inversely with period of survival. Median survival time was longer in patients younger than 50 years of age at diagnosis than in older patients (185 vs. 36 weeks; p < 0.001). Patients with preoperative symptoms for more than 6 months survived longer than those with a shorter duration of symptoms (median 228.1 vs. 110.2 weeks; p < 0.05). Seizures as the first symptom were associated with a longer median survival time ( 185.7 vs. 80 weeks, p < 0.01 ). There were no significant differences in median survival time between patients with and those without perivascular lymphocytic infiltration (135 vs. 139 weeks). One patient in Group A with a bromodeoxyuridine labeling index of less than 1% survived 60 weeks. Three patients in Group B with labeling indices of 1.1%, 6.5%, and 7.0% survived for 31, 41, and 106 weeks, respectively.
FIG. 3. Kaplan-Meier survival curves for all 28 patients
and for those in Group A ("pure" gemistocytic astrocytoma) and Group B ("mixed" gemistocytic astrocytoma). Numbers in parentheses represent the ratio of survivors (and one censored patient) to the total number of patients in each group.
The extent of resection also influenced outcome. The four patients who underwent gross total resection were still alive at the time of analysis, 117, 231, 310, and 460 weeks postoperatively. Of the five patients who had a biopsy only, four died after 10, 53, 80, and 153 weeks, and the remaining patient died of a pulmonary embolism after 48 weeks. All patients who underwent gross total resection had frontal tumors; more eloquent areas were affected in the biopsied patients (four with a parietal and one with an occipital tumor).
Discussion

Histopathologieal Considerations
In 1935, Elvidge, et at., 12 introduced gemistocytic astrocytomas as a subtype of astrocytoma, defining them as tumors consisting of "an almost pure culture of gemistocytes" (gemistocytic astrocytes). The term gemistocyte (from the Greek word gemistos, meaning "filled up") describes a large (15-to 40-urn), round-tooval cell with abundant cytoplasm. 2~ Gemistocytic astrocytes are not found in normal brain but generally result from pathological conditions affecting brain tissue, including infiltration by neoplastic astrocytomas. ~2
The origin and significance of these cells are uncertain. In an autoradiographic study of gliomas, Hoshino, et al., 2~ found no labeled gemistocytes in biopsy specimens and only small foci of labeled gemistocytes in autopsy specimens. They concluded that gemistocytic astrocytes cannot synthesize deoxyribonucleic acid (DNA), but occasionally incorporate tritiated thymidine in" their original state as fibrillary or protoplasmic astrocytes, thereafter undergoing transformation into gemistocytic astrocytes and entering the nonproliferating pool. According to these authors, gemistocytes merely reflect the intense proliferative activity of surrounding cells but are relatively inert themselves. This hypothesis, however, does not explain the frequent observation of aggressive growth in these tumors consisting predominantly of gemistocytes. 2~
The histopathological features of gemistocytic astrocytomas have not been well defined. Indeed, Kernohan and Sayre 23 included these tumors in Grade 1 (gemistocytic astrocytoma) as well as in Grade 2 (gem~istete cell astrocytoma) of their classification system. 23 The WHO 56 defines gemistocytic astrocytoma as a tumor composed "predominantly" of gemistocytic astrocytes; no further description is offered of the gemistocytic component or, surprisingly, of the astrocytic component. Glanzmann, et al., 16 attempted to explain the differences in survival times between patients with gemistocytic astrocytoma by distinguishing between "welldifferentiated" and "anaplastic" gemistocytic astrocytomas, but their criteria were not clearly defined.
Foci of gemistocytes may be found in any type of astrocytoma, especially diffuse fibrillary astrocytomas and glioblastomas multiforme. ~238' 4~ This makes sampling errors a crucial issue in the pathological diagnosis of brain tumors. Consequently, the diagnosis of "pure" gemistocytic astrocytoma in four biopsy specimens is debatable and might reflect foci of gemistocytes within a glioblastoma multiforme, for which the prognosis is accordingly worse. Owing to the lack of autopsy data, we cannot evaluate this possibility; however, exclusion of these four patients from the "pure" gemistocytic astrocytoma group did not significantly alter the median survival time (136.5 vs. 149 weeks for the remaining nine patients) and they were therefore included in the final analysis.
Perivascular lymphocyte infiltration has been reported in 30% to 89% ofgliomas. 2' 3"34-36"3~ An especially strong association has been noted between this feature and gemistocytic astrocytoma. Takeuchi and Barnard 5~ identified perivascular lymphocytic infiltration in 31 (28%) of 111 supratentorial astrocytomas and in 21 (62%) of 34 gemistocytic astrocytomas; however, their criteria for diagnosing gemistocytic astrocytomas were less strict than ours. Perivascular lymphocytic infiltration was present in 15 (54%) of 28 tumors in our series. Lymphocytic infiltration, especially perivascular lymphocytic infiltration, in gliomas has variously been found to improve the duration of survival, 3"4"9' 29'3 exert no influence on survival time, 6, 7, 37, 43 and reduce the survival period. 39'5t In our series, there was no significant difference in median survival times between patients with and those without perivascular lymphocytic infiltration (135 vs. 139 weeks, respectively).
Malignant transformation of lower-grade astrocytomas is reportedly frequent, 5' 243~ occurring in as many as 65% of patients. 3~ Russell and Rubinstein 3~ noted conversion to glioblastoma multiforme in 80% of their cases of gemistoeytic astrocytoma. In our seties, however, only one of 12 recurrent tumors showed malignant transformation. This discrepancy may be explained by our lack of autopsy data and by our strict histopathological criteria for diagnosing glioblastoma multiforme, according to which the mere presence of necrosis after irradiation or chemotherapy does not necessarily indicate malignant transformation.
In this study, the bromodeoxyuridine labeling index was obtained in only four tumors. In contrast to recent conclusions of Hoshino, et al., ~8 prognostic implications cannot be inferred from the results of labeling studies in these few cases. One patient whose "pure" gemistocytic astrocytoma had a bromodeoxyuridine labeling index of less than l% survived 60 weeks, while three patients whose "mixed" gemistocytic astrocytomas had labeling indices of 1.1%, 6.5%, and 7.0% survived 31, 41, and 106 weeks, respectively. All of the labeled cells were anaplastic astrocytes. The absence of bromodeoxyuridine-labeled gemistocytes in these specimens seems to support previous findings that the proliferative potential of gemistocytes is extremely low. ~5,2o The discrepancy between the behavior of individual gemistocytes and the frequently aggressive growth of gemistocytic astrocytomas is therefore still unexplained.
Clinical Considerations
Clinical data on patients with gemistocytic astrocytomas are scarce. ~~ ~, 28 Elvidge, et al., ~2 noted the exclusively supratentorial occurrence of gemistocytic astrocytomas which we also found in our series. In other series, ~'28 the male-to-female ratio was approximately 3:2, which corresponds to the ratio for all astrocytomas. 4~ In our series, males predominated by a ratio of 3:1 overall and by 12:1 among patients with "pure" gemistocytic astrocytoma. The median age at diagnosis (42.4 years) was similar to that reported by other authors (38.2 years l~ and 40 years28). The median age of our patients with "pure" gemistocytic astrocytomas, however, was 48.5 years.
Elvidge and Martinez-ColP ~ reported 18 patients with gemistocytic astrocytoma, presumably diagnosed according to the criteria of Elvidge, et al. ~2 Their mean survival time was 42.7 months; eight patients survived 4 years or longer and one lived 10 years 4 months. In the series of Levy and Elvidge, 28 the mean survival time was 31 months in 18 patients who had incomplete resection and 46 months in those who had complete resection. The mean survival time was 26 months for the 19 patients who died and 70 months for the five patients who were still alive. These data are difficult to interpret because postoperative radiation therapy was not used routinely.
In a report on the role of radiation therapy in the treatment of astrocytomas, Leibel, et al., 25 found only one of 1 1 patients with gemistocytic astrocytoma who survived more than 5 years. In a similar report of 77 patients, Glanzmann, et al., '6 described six "well-differentiated" and nine "anaplastic" gemistocytic astrocytomas. Three of the patients with well-differentiated gemistocytic astrocytomas lived 5 years and one lived 10 years; in contrast, no patient with anaplastic gemistocytic astrocytoma lived longer than 6 years. Several authors j38"4~' 44 have mentioned the unfavorable clinical course of gemistocytic astrocytoma without providing specific survival data or numbers of patients. In a recent report of radiation therapy for low-grade supratentorial astrocytomas, Shaw, et at.,48 described 17 patients with gemistocytic astrocytoma, as defined by the WHO? 6 They found the gemistocytic subtype to be associated with shorter survival times but did not present survival data for this subgroup.
Our efforts to clarify the biological and clinical behavior of gemistocytic astrocytomas are based on histopathological criteria that differentiate between "pure" gemistocytic astrocytoma (> 60% gemistocytes with a background of fibrillary astrocytes) and "mixed" gemistocytic astrocytoma (20% to 60% gemistocytes with a background of anaplastic astrocytes). Although both groups received similar treatment, there was little difference in median survival time (136.5 vs. 135.6 weeks); this was less than in patients with anaplastic astrocytomas treated with postoperative radiation therapy and adjuvant chemotherapy with CCNU, procarbazine, and vincristine (157 weeks) 27 and was similar to that in patients with atypical and anaplastic astrocytomas (28 and 36 months, respectively). 3~32 Moreover, the 5-year survival rate in our series was considerably less than in recent studies of patients with low-grade astrocytomas treated with postoperative radiation therapy (23.8% vs. 50% to 60%)234s49 The only significant difference in prognostieally important variables between groups was the somewhat younger median age of patients with "mixed" gemistoeytic astroeytomas which, if anything, would have a favorable influence on prognosis. Thus, despite its nonanaplastic morphology and the nonproliferative character of its predominant cellular component, "pure" gemistocytic astrocytomas in our series were as aggressive clinically as "mixed" gemistocytic astrocytomas, which have more anaplastic astrocytic features.
The prognostic importance of age, duration of preoperative symptoms, and seizures at presentation among patients with gliomas has been well documented. 7' 46-52 Our study confirms the favorable impact on survival time of the following features: age less than 50 years, preoperative symptoms lasting more than 6 months, and the occurrence of seizures as the initial symptom. Our findings also support the importance of the extent of surgical resection as a prognostic variable in glioma patients. ~' 4~
Conclusions
Our findings suggest that the presence of at least 20% gemistocytes in a glial neoplasm is an unfavorable prognostic sign, regardless of whether the surrounding background has more fibrillary or more anaplastic astrocytic components. We propose that such tumors be classified as anaplastic astrocytomas and be considered "high-grade" rather than "low-grade" astrocytomas. These tumors should be resected as extensively as feasible and be treated postoperatively with focal radiation therapy followed by nitrosourea-based chemotherapy.
